SP

Shivam Pandey

Active Director Director DIN 10974354
DIN 10974354 First appointment Feb 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Shivam Pandey

Data last updated:

Shivam Pandey is a Director at Axogenix Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 10974354
Primary Designation Director
Industry Pharma
First Appointment 27 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Feb 20252025Active

Board colleagues of Shivam Pandey

Directorship timeline

Open interactive timeline →
Axogenix Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Shivam Pandey

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shivam Pandey

Shivam Pandey currently holds 1 directorship: Axogenix Pharmaceuticals Private Limited (Director, since 27 Feb 2025).

Shivam Pandey was first appointed on 27 Feb 2025 as Director at Axogenix Pharmaceuticals Private Limited.

The current boards of Shivam Pandey's companies include Ashish Tiwari (Axogenix Pharmaceuticals Private Limited), Nilakshee Shesh Kumar Tiwari (Axogenix Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available